X4 Pharmaceuticals Inc
NASDAQ:XFOR
X4 Pharmaceuticals Inc
NASDAQ:XFOR
Price:
1.115 USD
3.24%
Market Closed
Updated:
May 3, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of XFOR.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
XFOR
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
XFOR Competitors Multiples
X4 Pharmaceuticals Inc Competitors
X4 Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
X4 Pharmaceuticals Inc
NASDAQ:XFOR
|
186.7m USD | 0 | -1.8 | -1.2 | -1.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.4B USD | 6 | 25.1 | 18 | 27 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
103.5B USD | 7.9 | 26.2 | 17.6 | 19.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.3B USD | 10.5 | 28.5 | 22.8 | 23.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.4 | 21.5 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 166 | 6.7 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.9B USD | 6.9 | -10 | -10.8 | -9.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
